5934-55-4

Basic information

• Product Name: IBOGAINE HYDROCHLORIDE--DEA*SCHEDULE I I TEM
• Synonyms: 12-methoxy-ibogaminmonohydrochloride;ibogaine,monohydrochloride;IBOGAINE HYDROCHLORIDE--DEA*SCHEDULE I I TEM;12-methoxyibogamine monohydrochloride
• CAS NO: 5934-55-4
• Molecular Formula: C₂₀H₂₆N₂O*ClH
• Molecular Weight: 346.899
• EINECS: 227-687-1
• Mol File: 5934-55-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 484.2°C at 760 mmHg
• Flash Point: 246.6°C
• Appearance: /
• Vapor Pressure: 1.57E-09mmHg at 25°C
• Solubility: H2O: soluble
• CAS DataBase Reference: IBOGAINE HYDROCHLORIDE--DEA*SCHEDULE I I TEM(CAS DataBase Reference)
• NIST Chemistry Reference: IBOGAINE HYDROCHLORIDE--DEA*SCHEDULE I I TEM(5934-55-4)
• EPA Substance Registry System: IBOGAINE HYDROCHLORIDE--DEA*SCHEDULE I I TEM(5934-55-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-26-37/39-45
• RIDADR: 1544
• WGK Germany: 3
• RTECS: NH6730000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 5934-55-4(Hazardous Substances Data)

Usage

Uses

Ibogaine Hydrochloride is a naturally occurring psychoactive substance. It is a β-carboline derivative that cause both hallucinations and tremor.

InChI:InChI=1/C20H26N2O.ClH/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19;/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3;1H/t12-,13+,17+,20+;/m1./s1

Upstream product

• 83-74-9 ibogaine 
• 510-22-5 voacangine 

Relevant articles and documents

A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats

Anecdotal reports and open-label case studies in humans indicated that the psychedelic alkaloid ibogaine exerts profound antiaddictive effects. Ample preclinical evidence demonstrated the efficacy of ibogaine, and its main metabolite, noribogaine, in substance-use-disorder rodent models. In contrast to addiction research, depression-relevant effects of ibogaine or noribogaine in rodents have not been previously examined. We have recently reported that the acute ibogaine administration induced a long-term increase of brain-derived neurotrophic factor mRNA levels in the rat prefrontal cortex, which led us to hypothesize that ibogaine may elicit antidepressant-like effects in rats. Accordingly, we characterized behavioral effects (dose- and time-dependence) induced by the acute ibogaine and noribogaine administration in rats using the forced swim test (FST, 20 and 40 mg/kg i.p., single injection for each dose). We also examined the correlation between plasma and brain concentrations of ibogaine and noribogaine and the elicited behavioral response. We found that ibogaine and noribogaine induced a dose- and time-dependent antidepressant-like effect without significant changes of animal locomotor activity. Noribogaine's FST effect was short-lived (30 min) and correlated with high brain concentrations (estimated >8 μM of free drug), while the ibogaine's antidepressant-like effect was significant at 3 h. At this time point, both ibogaine and noribogaine were present in rat brain at concentrations that cannot produce the same behavioral outcome on their own (ibogaine ～0.5 μM, noribogaine ～2.5 μM). Our data suggests a polypharmacological mechanism underpinning the antidepressant-like effects of ibogaine and noribogaine.